About the Authors
- Gargi Roy
-
Roles Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing
* E-mail: royg@medimmune.com (GR); m.bowen@miami.edu (MB)
Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Shu Zhang
-
Roles Methodology, Visualization
Current address: Biologics Development, Gilead Sciences, San Diego, California, United States of America
Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Lina Li
-
Roles Data curation, Investigation, Methodology
Affiliation Cell Culture and Fermentation Sciences, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Eileen Higham
-
Roles Project administration
Current address: Process Development, Juno Therapeutics, Seattle, Washington, United States of America
Affiliation Cell Culture and Fermentation Sciences, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Herren Wu
-
Roles Funding acquisition, Writing – review & editing
Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Marcello Marelli
-
Roles Writing – original draft, Writing – review & editing
Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America
- Michael A. Bowen
-
Roles Conceptualization, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing
* E-mail: royg@medimmune.com (GR); m.bowen@miami.edu (MB)
Current address: Analytical Development, Juno Therapeutics, Seattle, Washington, United States of America
Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America
Competing Interests
This study was funded by MedImmune LLC. Gargi Roy, Shu Zhang, Lina Li, Eileen Higham, Herren Wu, Marcello Marelli and Michael A Bowen were employed by MedImmune during study design, data collection and analysis and decision to publish. The cell lines used in the study express proprietary products that are currently in clinical development and so cannot be made available. This alters the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. However, the described experimental strategy has applicability for other recombinant proteins produced from CHO cells and the relevant methods are shared in detail in the article for others to use.